Helix Acquisition Corp. II completes $184M IPO and $5M private placement; trust funded

BridgeBio Oncology Therapeutics, Inc.

IPO of 18.4M Class A shares at $10.00 each included full exercise of 2.4M over-allotment shares.
Private sale of 509,000 Class A shares to sponsor Helix Holdings LLC at $10.00/share, gross $5.09M.
Net proceeds of $184M (including $5.52M deferred underwriting fee) deposited into trust account.
Audited balance sheet at Feb 13, 2024: $184M in trust, $2.5M cash, $3.2M shareholders' deficit.
SPAC focused on healthcare; must complete initial business combination within 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.